1	Assessment of Commercial SARS-CoV-2 Antibody Assays, Jamaica
2	
3	Tiffany R. Butterfield ^{a,1} , Alrica Bruce-Mowatt ^{a,1} , Yakima Z. R. Phillips ^a , Nicole Brown ^a , Keisha
4	Francis ^a , Jabari Brown ^b , Devon Taylor ^c , Carl A. Bruce ^d , Donovan McGrowder ^b , Gilian Wharfe ^b ,
5	Simone L. Sandiford ^e , Tamara K. Thompson ^f , Joshua J. Anzinger ^{a,g*}
6	
7	^a The University of the West Indies, Department of Microbiology, Kingston, Jamaica, West
8	Indies
9	^b The University of the West Indies, Department of Pathology, Kingston, Jamaica, West Indies
10	^c AstraZeneca, Department of Oncology Research, Gaithersburg, Maryland, United States of
11	America
12	^d The University of the West Indies, Department of Surgery, Kingston, Jamaica, West Indies
13	^e The University of the West Indies, Department of Basic Medical Sciences, Kingston, Jamaica,
14	West Indies
15	^f The University of the West Indies, Department of Medicine, Kingston, Jamaica, West Indies
16	^g Global Virus Network, Baltimore, MD, United States of America
17	
18	¹ Equal contribution
19	
20	*Corresponding Author. Email address joshua.anzinger@uwimona.edu.jm (J. Anzinger)
21	
22	
23	Word Count: 1230

24 Abstract

The performance of the Roche Elecsys® Anti-SARS-CoV-2, Abbott Architect SARS-CoV-2 25 26 IgG, Euroimmun SARS-CoV-2 IgA, Euroimmun SARS-CoV-2 IgG ELISA, and Trillium 27 IgG/IgM rapid assays was evaluated in Jamaica, the largest country of the English-speaking 28 Caribbean. Diagnostic sensitivities of the assays were assessed by testing serum samples from 29 SARS-CoV-2 PCR-confirmed persons. Serum samples collected ≥ 14 days after onset of 30 symptoms, or ≥ 14 days after an initial SARS-CoV-2 RT-PCR positive test for asymptomatics, 31 showed diagnostic sensitivities ranging from 67.9-75.0% when including all possible disease 32 severities and increased to 90.0-95.0% when examining those with moderate to critical disease. 33 Grouping moderate to critical disease showed a significant association with a SARS-CoV-2 34 antibody positive result for all assays. Diagnostic specificity, assessed by testing serum samples 35 collected during 2018-2019 from healthy persons and from persons with antibodies to a wide 36 range of viral infections, ranged from 96.7-100.0%. For all assays examined, SARS-CoV-2 real-37 time PCR cycle threshold (Ct) values of the initial nasopharyngeal swab sample testing positive 38 were significantly different for samples testing antibody positive versus negative. These data 39 from a predominantly African descent Caribbean population shows comparable diagnostic sensitivities and specificities for all testing platforms assessed and limited utility of these tests for 40 41 persons with asymptomatic and mild infections.

- 42
- 43

⁴⁴ Keywords: COVID-19; SARS-CoV-2; Antibody; Serology; Caribbean; Jamaica

45 **1. Introduction**

46	The SARS-CoV-2 pandemic has resulted in an unprecedented need for reliable commercial
47	laboratory diagnostics. While SARS-CoV-2 antibody assays have recently become commercially
48	available, performance data have mainly assessed high-income country populations. Assessment
49	of SARS-CoV-2 antibody assay performance in populations of mostly African descent is
50	lacking. To our knowledge, there has been no published performance assessment of SARS-CoV-
51	2 antibody assays with a predominantly black population. In this study in Jamaica, serum
52	samples were used to assess the diagnostic sensitivity and specificity of five commercial SARS-
53	CoV-2 antibody assays: Roche Elecsys® Anti-SARS-CoV-2, Abbott Architect SARS-CoV-2
54	IgG, Euroimmun SARS-CoV-2 IgA and IgG ELISAs, and Trillium IgG/IgM rapid diagnostic
55	test.
56	
57	2. Materials and methods

For diagnostic sensitivity analysis, 42 blood samples collected in tubes without coagulant were obtained from 37 consenting persons testing SARS-CoV-2 real-time PCR positive. Disease severity was classified according to WHO criteria. Real-time PCR of nasopharyngeal swabs samples was performed at the Jamaica National Influenza Centre according to the Corman *et al* method [1]. Samples were collected 6-103 days after disease onset for symptomatic persons and 20-69 days after a positive real-time PCR test for asymptomatic persons.

64 For the assessment of diagnostic specificity, archival 2018-2019 serum samples from the

65 University of the West Indies Virology Laboratory were identified. All samples were stored at -

66 20°C. The specificity panel included serum samples testing positive for Zika virus IgM,

67 chikungunya virus IgM, dengue virus IgM, CMV IgM, CMV IgG, EBV IgM, parvovirus B19

IgM, anti-HTLV-I/II, HIV Ag/Ab, HBsAg, anti-HCV, convalescent samples from patients
seroconverting for influenza A or B virus antibodies, convalescent samples from patients with
respiratory disease but without seroconversion for influenza A and B virus antibodies, healthy
persons requesting vaccination status, and women seeking routine antenatal care (Supplementary
Table).

73

74 The detection of antibodies was conducted with an Architect i2000SR for the Architect SARS-CoV-2 IgG assay, a cobas[®] 6000 analyzer for the Elecsys[®] Anti-SARS-CoV-2 assay, a Thermo 75 76 Scientific Multiskan FC Microplate Photometer for the Euroimmun SARS-CoV-2 IgA and IgG 77 ELISAs and lateral flow assay rapid test for the Trillium IgG/IgM assay. Each manufacturer's instructions were used for cutoff index values for the Elecsys[®], Architect, and Euroimmun 78 79 platforms, and the appearance of a line of any intensity for the control and/or IgG and IgM for 80 the Trillium IgG/IgM rapid test. Index values ≥ 1.0 are considered positive and index values < 1.081 are considered negative for the Elecsys® Anti-SARS-CoV-2 assay. For the Architect SARS-82 CoV-2 IgG assay index values \geq 1.4 are considered positive and index values < 1.4 are considered negative. For both Euroimmun SARS-CoV-2 ELISAs, index values ≥1.1 are considered positive, 83 84 \geq 0.8-<1.1 are considered borderline, and <0.8 are considered negative. Borderline index values 85 were considered negative.

86

B7 Data were analyzed using IBM SPSS Statistics[®] for Windows version 20. Categorical variables 88 were reported using proportions and continuous variables reported as mean with standard 89 deviation. Comparison of means was by Welch's t-test while associations between categorical 90 variables were assessed using the γ^2 test.

91

92 This study was approved by the UWI Mona Campus Research Ethics Committee (ECP 244
93 19/20).

94

95 **3. Results**

96 Diagnostic specificity of each assay was examined with a panel of archived serum samples

97 predating the introduction of SARS-CoV-2 into Jamaica. The specificity was 100.0% (104/104)

98 for Elecsys[®] Anti-SARS-CoV-2, 98.2% (109/111) for Architect SARS-CoV-2 IgG, 97.5%

99 (119/122) for Euroimmun SARS-CoV-2 IgA, 100.0% (122/122) for Euroimmun SARS-CoV-2

100 IgG, 96.7% (87/90) for Trillium IgM, and 98.9% (89/90) for Trillium IgG (Supplementary

101 Table).

102

103 Diagnostic sensitivities of the assays ranged from 42.9-71.4% for samples collected 6-9 days 104 after onset of symptoms, 85.7-100.0% for samples collected 10-13 days after onset of symptoms, 105 and 90.0-95.0% for samples collected \geq 14 days after onset of symptoms (Fig. 1). As samples 106 from asymptomatic and mildly affected persons were only available for collections ≥ 14 days 107 after onset of symptoms or after an initial SARS-CoV-2 PCR test, we examined sensitivities for 108 all disease severities separately. For all assays, sensitivities were lower when asymptomatic and 109 mild infections were included, ranging from 67.9-75.0% (Fig. 1). When moderate, severe and 110 critical disease was grouped, for each assay there was a significant association between this group and testing antibody positive: Elecsys[®] Anti-SARS-CoV-2 (χ^2 =19.03, p=0.001), Architect 111 SARS-CoV-2 IgG (χ^2 =15.72, p=0.003), Euroimmun SARS-CoV-2 IgA (χ^2 =21.11, p=0.007), 112

113	Euroimmun SARS-CoV-2 IgG (χ^2 =18.77, <i>p</i> =0.016), and Trillium IgM (χ^2 =11.59, <i>p</i> =0.021) and
114	IgG ($\chi^2=17.20$, $p=0.002$). Detection of antibodies was highly congruent between assays (Fig. 2).
115	
116	The low diagnostic sensitivity across testing platforms for asymptomatic and mild SARS-CoV-2
117	infections led us to question whether a relationship exists between the presence of antibodies and
118	relative SARS-CoV-2 viral load at laboratory diagnosis. SARS-CoV-2 real-time PCR cycle
119	threshold (Ct) values were compared with the presence of antibodies from patients with samples
120	collected \geq 14 days after onset of symptoms or an initial SARS-CoV-2 PCR. Ct values were
121	significantly different between samples testing positive and negative for all assays examined
122	(Fig. 3). For the Elecsys® Anti-SARS-CoV-2, Architect SARS-CoV-2 IgG, Euroimmun SARS-
123	CoV-2 IgG, and Trillium IgG assays, the mean Ct value was 23.5 ± 5.7 for samples testing
124	antibody positive and 34.6 ± 1.0 for samples testing antibody negative. Mean Ct values for
125	Euroimmun IgA were 24.0 ± 5.7 for samples testing antibody positive 31.8 ± 6.8 for samples
126	testing antibody negative, and for Trillium IgM, 23.0 ± 5.8 for samples testing antibody positive
127	and 33.5 ± 2.8 for samples testing antibody negative.
128	

129 4. Discussion and conclusions

Our data examining two chemiluminescent assays, two ELISA assays and one rapid test show that the diagnostic sensitivity of these assays for SARS-CoV-2 antibodies is comparable. Each of the tests examined in this study are approved by the FDA and are CE marked, except for the new Trillium IgM/IgG rapid diagnostic test. The similar diagnostic sensitivity and specificity of the Trillium IgM/IgG rapid diagnostic test with chemiluminescent and ELISA assays makes this test

suitable for resource limited laboratories lacking high cost instruments and those that may runlaboratory-based assays infrequently in batches.

137

138 An accumulating body of evidence indicates that after a SAR-CoV-2 infection antibodies

become detectable approximately one week after disease onset [2]. In agreement with these

- 140 studies, approximately half of the SARS-CoV-2 infected persons in our study had detectable
- 141 antibodies 6-9 days after onset of symptoms, with most having antibodies ≥ 10 days after
- 142 symptom onset.

143

144 The high sensitivities for moderate to critical SARS-CoV-2 infections for each of the assays

examined is consistent with previous studies [2]. When asymptomatic and mild groups were

146 included in our analysis, sensitivities decreased for all assays. Previous studies have shown that

147 asymptomatic persons are less likely than symptomatic persons of having detectable SARS-

148 CoV-2 antibodies [3,4].

149

150 Comparing SARS-CoV-2 antibody results revealed a striking difference in relative viral loads 151 (Ct values) between persons testing antibody negative or positive, with patients testing antibody 152 negative having significantly lower viral loads than patients testing antibody positive. These data 153 are consistent with a recently published study examining SARS-CoV-2-infected asymptomatic 154 contacts and outpatients showing that SARS-CoV-2 real-time PCR Ct values are inversely 155 related to SARS-CoV-2 IgG index values using the Euroimmun SARS-CoV-2 IgG ELISA assay 156 [4]. High SARS-CoV-2 viral loads could cause a more robust adaptive immune response leading 157 to production of high levels and quality of SARS-CoV-2 antibodies.

1	5	8
---	---	---

159	Our data assessing a Caribbean population of predominantly African descent highlights the				
160	limited diagnostic sensitivity of the assays examined for persons with asymptomatic and mild				
161	SARS-CoV-2 infections. This finding has important implications for future seroprevalence				
162	studies in which a sizable proportion of the SARS-CoV-2-infected population may have				
163	experienced no symptoms or mild disease.				
164					
165	Declaration of competing interest				
166	All authors declared no conflict of interest.				
167					
168	Acknowledgements				
169	As a Global Infectious Diseases Scholar, Tiffany Butterfield received mentored research training				
170	in the development of this manuscript. This training was supported in part by the University at				
171	Buffalo Clinical and Translational Science Institute award UL1TR001412 and the Global				
172	Infectious Diseases Research Training Program award D43TW010919. The content is solely the				
173	responsibility of the authors and does not necessarily represent the official views of the Clinical				
174	and Translational Science Institute or the National Institutes of Health.				
175					
176	References				
177	1. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of				
178	2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 2020 Jan				
179	23;25(3):2000045.				
180	2. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al.				

- 181 Antibody tests for identification of current and past infection with SARS-CoV-2.
- 182 Cochrane Database Syst Rev. 2020;2(6):1–306.
- 183 3. Wellinghausen N, Plonné D, Voss M, Ivanova R, Frodl R, Deininger S. SARS-CoV-2-IgG
- 184 response is different in COVID-19 outpatients and asymptomatic contact persons. J Clin
- 185 Virol. 2020 Sep 1;130:104542.
- 186 4. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological
- 187 assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(August).







199 Fig. 2. Agreement between SARS-CoV-2 antibody assays. Results for all samples tested for each

200 antibody testing platform are shown. Positive results are shown in white, borderline results in

- 201 light grey, and negative results in dark grey.
- 202
- 203



204

205 Fig. 3. SARS-CoV-2 PCR cycle threshold values for samples testing SARS-CoV-2 antibody

206 negative or positive samples. Sera from SARS-CoV-2 RT-PCR confirmed persons was collected

 ≥ 14 days after onset of symptoms or ≥ 14 after a positive SARS-CoV-2 RT-PCR test for

208 asymptomatics. Results were identical for all platforms with the exception of Euroimmun SARS-

209 CoV-2 IgA that tested borderline (open circle) and Trillium IgM that tested negative (open

square). Differences between groups was highly significant for all testing platforms. p = < 0.0001

- 211 for Elecsys® Anti-SARS-CoV-2, Architect SARS-CoV-2 IgG, Euroimmun SARS-CoV-2 IgG,
- and Trillium IgG. *p*=<0.0003 for Euroimmun SARS-CoV-2 IgA and Trillium IgM.